Corrigendum to “Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia”
Main Authors: | Scott McPherson, Getinet Tafese, Temesgen Tafese, Sinknesh Wolde Behaksra, Hiwot Solomon, Birhanu Oljira, Hirpa Miecha, Kaleab A. Debebe, Biruck Kebede, Teshome Gebre, Fikreab Kebede, Fikre Seife, Fentahun Tadesse, Belete Mammo, Abraham Aseffa, Anthony W. Solomon, David C.W. Mabey, Michael Marks, Endalamaw Gadisa |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | EClinicalMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023002973 |
Similar Items
-
Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in EthiopiaResearch in context
by: Scott McPherson, et al.
Published: (2023-05-01) -
Perceptions and acceptability of co-administered albendazole, ivermectin and azithromycin mass drug administration, among the health workforce and recipient communities in Ethiopia.
by: Scott McPherson, et al.
Published: (2023-10-01) -
Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review.
by: Scott McPherson, et al.
Published: (2023-06-01) -
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response
by: Daniel Abebe Mekonnen, et al.
Published: (2023-04-01) -
A 36-year-old lady with type three female genital mutilation (Infibulation) – its long-term complications: a case report and literature review
by: Tafese Dejene Jidha, et al.
Published: (2023-05-01)